

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SUNSHINE LAKE PHARMA CO., LTD.**

**廣東東陽光藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6887)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders and potential investors of the Company that, based on the unaudited management accounts currently available to the Group and a preliminary estimate by the Company’s management, the Group is expected to record a net profit attributable to the parent company of approximately RMB0.27 billion for the year ended 31 December 2025, representing an increase of approximately 228.57% compared to the net loss attributable to the parent company of approximately RMB0.21 billion recorded for the corresponding period last year.

The anticipated increase is primarily attributable to a substantial year-on-year growth in demand for the Group’s core product, Oseltamivir Phosphate, which, as a widely recognised treatment and prophylactic for influenza with proven efficacy and a strong brand reputation, benefited from a markedly higher incidence of influenza outbreaks in the second half of 2025 compared to the corresponding period of the prior year. Concurrently, the Group adhered to its diversified market development strategy, continuously strengthening its academic promotion framework while optimising channel distribution and terminal coverage, thereby enhancing the market penetration, brand influence, and commercial value of its core products. In addition, other business pipelines also delivered robust performance.

Looking ahead, the Group will, while consolidating the commercialisation of its existing product pipelines and reinforcing its market position, focus on innovation and internationalisation strategies. On one hand, it will further accelerate the research, development, and commercialisation of key products, including innovative drugs and biologics, continuously enriching its product pipeline to drive the sustainable long-term growth of the Company’s business. On the other hand, the Group will continue to deepen technical exchanges and strategic collaborations with leading international pharmaceutical

companies, steadily advancing the global deployment of its products and market presence, thereby enhancing its capacity for long-term sustainable development and overall competitive strength.

The Company is still in the process of finalising the annual results of the Group for the year ended 31 December 2025. The information contained in this announcement is solely based on a preliminary assessment of the Company's management with the unaudited management accounts of the Group for the year ended 31 December 2025 and other information currently available to the Company, which has not been reviewed or audited by the auditors of the Company. Details of the financial information of the Group for the year ended 31 December 2025 will be disclosed in the annual results announcement of the Company, which is expected to be published by the end of March 2026.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Sunshine Lake Pharma Co., Ltd.**  
**Dr. ZHANG Yingjun**  
*Chairman*

Dongguan, the PRC  
13 March 2026

*As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.*